Menu Search
Equities

Nurexone Biologic Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
J90:STU

Nurexone Biologic Inc

Actions
  • Price (EUR)0.411
  • Today's Change0.00 / 0.00%
  • Shares traded2.00k
  • 1 Year change-1.20%
  • Beta0.2291
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nurexone Biologic Inc is an Israel-based company engaged primarily in the pharmaceutical sector. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s flagship product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications. The Company focuses on research and development of pharmaceutical technologies.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-8.96m
  • Incorporated2025
  • Employees9.00
  • Location
    Nurexone Biologic Inc1 Adelaide Street East, Suite 801HAIFA 3200003IsraelISR
  • Websitehttps://nurexone.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.